SE
MCID: STT001
MIFTS: 60

Status Epilepticus (SE)

Categories: Neuronal diseases, Rare diseases

Aliases & Classifications for Status Epilepticus

MalaCards integrated aliases for Status Epilepticus:

Name: Status Epilepticus 12 52 29 54 6 43 15 17 71 32
Grand Mal Status Epilepticus 71 32
Generalized Convulsive Status Epilepticus 52
Grand Mal Status 12
Gcse 52
Se 52

Classifications:



External Ids:

Disease Ontology 12 DOID:1824
MeSH 43 D013226
NCIt 49 C85079
SNOMED-CT 67 230456007
ICD10 32 G41 G41.0 G41.9
UMLS 71 C0038220 C0311335

Summaries for Status Epilepticus

MalaCards based summary : Status Epilepticus, also known as grand mal status epilepticus, is related to febrile infection-related epilepsy syndrome and epileptic encephalopathy, early infantile, 6, and has symptoms including seizures and symptomatic seizures. An important gene associated with Status Epilepticus is GALC (Galactosylceramidase), and among its related pathways/superpathways are Circadian entrainment and Neuropathic Pain-Signaling in Dorsal Horn Neurons. The drugs Oxcarbazepine and Carbamazepine have been mentioned in the context of this disorder. Affiliated tissues include brain, temporal lobe and cortex, and related phenotypes are behavior/neurological and growth/size/body region

Wikipedia : 74 Status epilepticus (SE) is a single seizure lasting more than five minutes or two or more seizures... more...

Related Diseases for Status Epilepticus

Diseases related to Status Epilepticus via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 792)
# Related Disease Score Top Affiliating Genes
1 febrile infection-related epilepsy syndrome 34.7 SCN1A POLG PCDH19
2 epileptic encephalopathy, early infantile, 6 33.4 SCN1A PVALB PCDH19 LGI1 GRIN2B
3 lennox-gastaut syndrome 33.4 SCN1A POLG PCDH19 GRIN2B
4 brain injury 31.3 GFAP ENO2 BDNF
5 early myoclonic encephalopathy 31.3 SCN1A POLG PCDH19
6 limbic encephalitis 31.3 LGI1 GRIN2B GRIA1
7 landau-kleffner syndrome 31.3 SCN1A PCDH19 GRIN2B
8 creutzfeldt-jakob disease 31.3 PVALB GFAP ENO2 BDNF
9 temporal lobe epilepsy 31.2 SCN1A PVALB NTRK2 NPY LGI1 GRIN2B
10 traumatic brain injury 31.2 GFAP ENO2 BDNF
11 epilepsy, myoclonic juvenile 31.2 SCN1A PVALB PCDH19 LGI1
12 epilepsy, idiopathic generalized 31.1 SCN1A PVALB POLG PCDH19 LGI1
13 west syndrome 30.9 SCN1A PVALB PCDH19 NTRK2 GRIN2B
14 encephalomalacia 30.9 LGI1 GFAP GALC BDNF
15 amnestic disorder 30.8 LGI1 GRIN2B GRIA1 FOS BDNF
16 epilepsy 30.8 SCN1A PVALB POLG PCDH19 NPY LGI1
17 depression 30.8 GRIA2 GRIA1 BDNF
18 electroclinical syndrome 30.7 SCN1A PVALB POLG PCDH19
19 benign epilepsy with centrotemporal spikes 30.7 SCN1A PCDH19 LGI1 BDNF
20 focal epilepsy 30.7 SCN1A PVALB PCDH19 NPY LGI1 GRIN2B
21 hydrocephalus 30.6 NPY GFAP ENO2 BDNF
22 childhood absence epilepsy 30.6 SCN1A PVALB PCDH19 LGI1 FOS
23 dystonia 30.6 PVALB POLG NPY GRIN2B GALC BDNF
24 migraine with or without aura 1 30.5 SCN1A POLG NPY GRIN2B GRIA1 FOS
25 toxic encephalopathy 30.5 NTRK2 GRIN2B GRIA1 GFAP BDNF
26 ganglioglioma 30.5 PVALB NTRK2 GFAP ENO2
27 anterograde amnesia 30.5 LGI1 GRIN2B FOS BDNF
28 anxiety 30.5 NTRK2 NPY GRIN2B BDNF
29 generalized epilepsy with febrile seizures plus 30.4 SCN1A PVALB PCDH19 LGI1
30 mental depression 30.4 NTRK2 GRIN2B GRIA1 BDNF
31 neonatal hypoxic and ischemic brain injury 30.4 PVALB ENO2 BDNF
32 psychotic disorder 30.4 PVALB GRIN2B GRIA1 BDNF
33 fragile x syndrome 30.3 PVALB GRIN2B GRIA2 GRIA1 BDNF
34 peripheral nervous system disease 30.3 POLG GFAP GAP43 BDNF
35 retrograde amnesia 30.2 GRIN2B GRIA1 FOS BDNF
36 early infantile epileptic encephalopathy 30.1 SCN1A PVALB POLG PCDH19 LGI1 GRIN2B
37 autosomal dominant nocturnal frontal lobe epilepsy 30.1 SCN1A PCDH19 LGI1
38 bipolar disorder 30.1 PVALB POLG NTRK2 GRIN2B GRIA2 GRIA1
39 optic nerve disease 30.0 POLG LGI1 JUN GFAP BDNF
40 attention deficit-hyperactivity disorder 30.0 NTRK2 NPY GRIN2B FOS BDNF
41 obsessive-compulsive disorder 30.0 NTRK2 NPY GRIN2B GRIA2 BDNF
42 major depressive disorder 29.8 PVALB NTRK2 NPY GRIN2B GRIA2 GRIA1
43 alzheimer disease 29.7 PVALB NTRK2 NPY JUN GRIN2B GRIA2
44 reflex epilepsy 29.6 SCN1A LGI1
45 autism spectrum disorder 29.5 SCN1A PCDH19 NPY GRIN2B GFAP GABRA4
46 schizophrenia 29.4 PVALB NTRK2 NPY GRIN2B GRIA2 GRIA1
47 parkinson disease, late-onset 29.3 PVALB POLG NTRK2 JUN GRIN2B GRIA2
48 neuroblastoma 29.3 NTRK2 NPY LGI1 JUN GFAP GAP43
49 autism 29.3 SCN1A PCDH19 NTRK2 GRIN2B GRIA2 GRIA1
50 new-onset refractory status epilepticus 13.1

Comorbidity relations with Status Epilepticus via Phenotypic Disease Network (PDN): (show all 17)


Acute Cystitis Alzheimer Disease
Bronchitis Cerebral Atherosclerosis
Decubitus Ulcer Deficiency Anemia
Encephalopathy Epilepsy, Focal, with Speech Disorder and with or Without Mental Retardation
Familial Atrial Fibrillation Heart Disease
Hypertension, Essential Hypothyroidism
Protein-Energy Malnutrition Respiratory Failure
Schizophreniform Disorder Swallowing Disorders
Transient Cerebral Ischemia

Graphical network of the top 20 diseases related to Status Epilepticus:



Diseases related to Status Epilepticus

Symptoms & Phenotypes for Status Epilepticus

UMLS symptoms related to Status Epilepticus:


seizures, symptomatic seizures

MGI Mouse Phenotypes related to Status Epilepticus:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.41 BDNF CALB1 ENO2 FOS GABRA4 GALC
2 growth/size/body region MP:0005378 10.28 BDNF ENO2 FOS GALC GAP43 GFAP
3 nervous system MP:0003631 10.26 BDNF CALB1 ENO2 FOS GABRA4 GALC
4 cellular MP:0005384 10.21 BDNF ENO2 FOS GALC GAP43 GFAP
5 mortality/aging MP:0010768 10.17 BDNF FOS GALC GAP43 GFAP GRIA2
6 hearing/vestibular/ear MP:0005377 9.85 BDNF CALB1 FOS GRIA2 NTRK2 POLG
7 no phenotypic analysis MP:0003012 9.76 BDNF GABRA4 GRIA1 GRIA2 GRIN2B JUN
8 normal MP:0002873 9.73 BDNF CALB1 FOS GABRA4 GFAP GRIA1
9 vision/eye MP:0005391 9.28 BDNF FOS GALC GAP43 GFAP JUN

Drugs & Therapeutics for Status Epilepticus

Drugs for Status Epilepticus (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 97)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Oxcarbazepine Approved Phase 4 28721-07-5 34312
2
Carbamazepine Approved, Investigational Phase 4 298-46-4 2554
3
Cisatracurium Approved Phase 4 96946-41-7
4 Sodium Channel Blockers Phase 4
5 Psychotropic Drugs Phase 4
6 Diuretics, Potassium Sparing Phase 4
7 Analgesics, Non-Narcotic Phase 4
8 Neuromuscular Blocking Agents Phase 4
9
Fosphenytoin Approved, Investigational Phase 3 93390-81-9 56339
10
Paraldehyde Approved, Investigational Phase 3 123-63-7 31264
11
Topiramate Approved Phase 3 97240-79-4 5284627
12
gamma-Aminobutyric acid Approved, Investigational Phase 2, Phase 3 56-12-2 119
13
Clonazepam Approved, Illicit Phase 3 1622-61-3 2802
14
Propofol Approved, Investigational, Vet_approved Phase 3 2078-54-8 4943
15
Thiopental Approved, Vet_approved Phase 3 76-75-5 3000715
16
Diazepam Approved, Illicit, Investigational, Vet_approved Phase 2, Phase 3 439-14-5 3016
17
Pentobarbital Approved, Investigational, Vet_approved Phase 3 76-74-4 4737
18
Acetazolamide Approved, Vet_approved Phase 2, Phase 3 59-66-5 1986
19
Clobazam Approved, Illicit Phase 3 22316-47-8 2789
20
Carvedilol Approved, Investigational Phase 2, Phase 3 72956-09-3 2585
21
Glutamic acid Approved, Nutraceutical Phase 2, Phase 3 56-86-0 33032
22
Aspartic acid Approved, Nutraceutical Phase 2, Phase 3 56-84-8 5960
23 Hypoglycemic Agents Phase 3
24 Soy Bean Phase 2, Phase 3
25 N-Methylaspartate Phase 2, Phase 3
26 Analgesics Phase 3
27 Gastrointestinal Agents Phase 2, Phase 3
28 Antiemetics Phase 2, Phase 3
29 Anti-Anxiety Agents Phase 2, Phase 3
30 diuretics Phase 2, Phase 3
31 Carbonic Anhydrase Inhibitors Phase 2, Phase 3
32 GABA Agonists Phase 3
33 Calcium, Dietary Phase 2, Phase 3
34 Adrenergic beta-Antagonists Phase 2, Phase 3
35 Adrenergic alpha-Antagonists Phase 2, Phase 3
36 Adrenergic Agents Phase 2, Phase 3
37 Antihypertensive Agents Phase 2, Phase 3
38 Hormones Phase 2, Phase 3
39 Antioxidants Phase 2, Phase 3
40 Adrenergic Antagonists Phase 2, Phase 3
41 Vasodilator Agents Phase 2, Phase 3
42 Adrenergic alpha-1 Receptor Antagonists Phase 2, Phase 3
43 polysaccharide-K Phase 2, Phase 3
44 calcium channel blockers Phase 2, Phase 3
45 Protective Agents Phase 2, Phase 3
46
Calcium Nutraceutical Phase 2, Phase 3 7440-70-2 271
47
Valproic acid Approved, Investigational Phase 2 99-66-1 3121
48
Sage Approved Phase 1, Phase 2
49
Coal tar Approved Phase 1, Phase 2 8007-45-2
50
Omeprazole Approved, Investigational, Vet_approved Phase 2 73590-58-6 4594

Interventional clinical trials:

(show top 50) (show all 119)
# Name Status NCT ID Phase Drugs
1 Effect of Carbamazepine and Oxcarbazepine on Serum Neuron-specific Enolase and S100B in Focal Seizures Completed NCT02705768 Phase 4 Carbamazepine;Oxcarbazepine
2 The Study of Pharmacokinetics and Pharmacodynamics of a Loading Dose Cisatracurium in Critically Ill Patients Completed NCT03337373 Phase 4 cisatracurium
3 Levetiracetam Versus Phenytoin in Management of Pediatric Status Epilepticus: a Randomized Clinical Trial Recruiting NCT04176887 Phase 4 Levetiracetam Injection;Phenytoin Injection
4 Efficacy of Ketamine in Refractory Convulsive Status Epilepticus in Children: a Multicenter, Randomized, Controlled, Open-label, No-profit, With Sequential Design Study. Unknown status NCT02431663 Phase 3 Ketamine
5 Efficacy of Low Glycemic Index Diet Therapy in Children With Refractory Epilepsy - A Randomized Controlled Trial Unknown status NCT01645072 Phase 3
6 Refractory Status Epilepticus: Plasmatic Levels Monitorization Utility Completed NCT01586208 Phase 3 valproic acid (VPA)
7 Comparison Between Lorazepam, Clonazepam and Clonazepam + Fosphenytoin for the Treatment of Out-of-hospital Generalized Status Epilepticus in Adults Patients Completed NCT01870024 Phase 3 Clonazepam;Fosphenytoin;Placebo;Lorazepam
8 A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of SAGE-547 Injection in the Treatment of Subjects With Super-Refractory Status Epilepticus Completed NCT02477618 Phase 3 SAGE-547;Placebo
9 Efficiency of Levetiracetam Intravenous in Association With Clonazepam Versus Clonazepam Alone in Prehospital Care of Generalised Tonicoclonic Status Epilepticus Completed NCT01150331 Phase 3 Levetiracetam/Clonazepam;Clonazepam/Placebo levetiracetam IV
10 A Multicenter, Randomized, Blinded, Comparative Effectiveness Study of Fosphenytoin, Valproic Acid, or Levetiracetam in the Emergency Department Treatment of Patients With Benzodiazepine-refractory Status Epilepticus. Completed NCT01960075 Phase 3 Fosphenytoin;Levetiracetam;Valproic acid
11 Phase III Randomized Study of Diazepam Vs Lorazepam Vs Placebo for Prehospital Treatment of Status Epilepticus Completed NCT00004297 Phase 3 diazepam;lorazepam
12 A Phase 3, Multicenter, Open-label Study to Determine the Efficacy, Safety, and Pharmacokinetics of Buccally Administered MHOS/SHP615 in Pediatric Patients With Status Epilepticus (Convulsive) in the Hospital or Emergency Room Completed NCT03336645 Phase 3 SHP615
13 A Multi-center, Open-label, Non-controlled Study To Evaluate The Efficacy And Safety Of Lorazepam Intravenously Administered In Subjects With Status Epilepticus Or Repetitive Status Epilepticus Completed NCT02239380 Phase 3 Lorazepam
14 A Randomised Trial to Compare the Efficacy and Safety of Intranasal Lorazepam and Intramuscular Paraldehyde in the Treatment of Convulsions in Children Completed NCT00116064 Phase 3 intranasal lorazepam;intramuscular paraldehyde
15 Intra-Nasal vs. Intra-Venous Lorazepam for Control of Acute Seizures in Children: Prospective Open Labeled Randomized Equivalence Trial Completed NCT00735527 Phase 3 Lorazepam;Lorazepam
16 Evaluation of the Interests of a Therapeutic Hypothermia Procedure in Convulsive Status EPILEPTICUS in Adults in Intensive Care - HYBERNATUS Study Completed NCT01359332 Phase 3
17 The Study of NPC-06 - Investigation of Safety, Efficacy and Pharmacokinetics of Fosphenytoin Completed NCT00908453 Phase 3 fosphenytoin
18 Use Of Lorazepam For The Treatment Of Pediatric Status Epilepticus: A Randomized, Double-Blinded Trial Of Lorazepam And Diazepam Completed NCT00621478 Phase 2, Phase 3 lorazepam or diazepam
19 A Double-blind Randomized Clinical Trial of the Efficacy of IM Midazolam Versus IV Lorazepam in the Pre-hospital Treatment of Status Epilepticus by Paramedics Completed NCT00809146 Phase 3 Intramuscular route of active treatment;Intravenous route of active treatment
20 Childhood Convulsive Status Epilepticus - In Search Of Optimal Drug Management In A Resource Limited Setting Completed NCT03650270 Phase 3 Phenobarbital
21 Internet Administration of the Modified Atkins Diet for Adults With Intractable Epilepsy Completed NCT00436631 Phase 3
22 Single Center TOPAMAX� (Topiramate) Monotherapy Trial in Subjects With Refractory Partial Onset Seizures Completed NCT00266591 Phase 3 topiramate
23 Evaluation Of The Efficacy Of The Modified Atkins Diet In Children With Refractory Epilepsy: A Randomized Controlled Trial. Completed NCT00836836 Phase 2, Phase 3
24 A Phase 3, Multicenter, Open-label Extension Study of Buccally Administered MHOS/SHP615 in Pediatric Patients With Status Epilepticus (Convulsive) in Community Settings Recruiting NCT03336450 Phase 3 SHP615;MHOS/SHP615
25 Efficacy of Ketamine Infusion Compared With Traditional Anti-epileptic Agents in Refractory Status Epilepticus- a Pilot Study Recruiting NCT03115489 Phase 2, Phase 3 Traditional Treatment (Group T);Ketamine Infusion (Group K)
26 Voices of Patients' Relatives to Support Weaning From Mechanical Ventilation in Patients With Severe Brain Injury - VOICE-WEANING, a Randomized Clinical Trial Recruiting NCT03795623 Phase 2, Phase 3
27 Initiating Ketamine in Acutely Suicidal Patients in the Emergency Department Enrolling by invitation NCT04260607 Phase 3 Ketamine Hydrochloride;Normal saline
28 A Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Intravenous Ganaxolone in Status Epilepticus Not yet recruiting NCT04391569 Phase 3 Ganaxolone;Placebo
29 Efficacy of add-on PEramPanel in Focal Motor Status Epilepticus Not yet recruiting NCT04309721 Phase 3 Perampanel;Placebo
30 A Randomized Clinical Trial for the Treatment of Refractory Status Epilepticus Terminated NCT00265616 Phase 3 propofol;thiopental/pentobarbital
31 Non-inferiority Prospective Randomized Trial of Acetazolamide Versus Diazepam in Patients With Continuous Spike and Wave in Sleep (CSWS)/Landau Kleffner Syndrome (LKS) Terminated NCT02904265 Phase 2, Phase 3 Diazepam;Acetazolamide
32 Buccal, Intranasal or Intravenous Lorazepam for the Treatment of Acute Convulsions in Children in Blantyre, Malawi: a Randomized Trial Terminated NCT00343096 Phase 3 Lorazepam
33 A Phase III, Randomized, Open Label, Single Center, Study on the Effects of Treatment of Epilepsia Partialis Continua With Clobazam Compared to Treatment With or in Addition to Lorazepam and/or Clonazepam Terminated NCT02134366 Phase 3 Clobazam;Clonazepam;Lorazepam
34 An Open-label Pilot Study Using Carvedilol-CR as a P-glycoprotein Inhibitor as Adjunct Therapy in the Treatment of Medically-refractory Epilepsy Terminated NCT00524134 Phase 2, Phase 3 Carvedilol-CR
35 Evaluation of Efficacy and Safety of Levetiracetam, Lacosamide and Ketamine as Adjunctive Treatment of Refractory Status Epilepticus Withdrawn NCT02726867 Phase 3 levetiracetam;lacosamide;Ketamine;Phenobarbital
36 Safety and Tolerability of Add-on Levetiracetam in Status Epilepticus Unknown status NCT00362141 Phase 2 levetiracetam (add-on)
37 Treatment of Nodding Syndrome - A Randomized Blinded Placebo-Controlled Crossover Trial of Oral Pyridoxine and Conventional Anti-Epileptic Therapy, in Northern Uganda — 2012 Unknown status NCT01730313 Phase 2 Pyridoxine;Sodium Valproate;Phenytoin;Placebo
38 Levetiracetam Versus Sodium Valproate in Children With Refractory Generalized Convulsive Status Epilepticus : An Open Randomized Study Completed NCT02920060 Phase 2 Intravenous levetiracetam;Sodium valproate
39 A Double-Blind Randomized, Placebo Controlled Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of Intravenous Ganaxolone as Adjunctive Therapy to Treat Subjects With Status Epilepticus Completed NCT03350035 Phase 2 Ganaxolone;Placebo
40 An Open-label Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of SAGE-547 Injection as Adjunctive Therapy for the Treatment of Super-Refractory Status Epilepticus Completed NCT02052739 Phase 1, Phase 2 SAGE-547
41 Open-label, Single-arm, Multi-center, Pharmacokinetic, Safety and Tolerability Study of Levetiracetam Intravenous Infusion in Children (4 - 16 Years Old) With Epilepsy. Completed NCT00535392 Phase 2 Levetiracetam
42 Impact of microEEG on Clinical Management and Outcomes of Emergency Department (ED) Patients With Altered Mental Status Completed NCT01671475 Phase 2
43 Open-label, Single-arm, Multi-center, Pharmacokinetic, Safety and Tolerability Study of Levetiracetam Intravenous Infusion in Children (1 Month- 4 Years Old) With Epilepsy Completed NCT00505934 Phase 2 Levetiracetam
44 Phenobarbital Versus Valproate for Generalized Convulsive Status Epilepticus in Adults: A Prospective Randomized Controlled Trial in China Recruiting NCT03025906 Phase 2 Phenobarbital;Valproate
45 An Open-label Non-randomized Phase IIa Trial to Evaluate Safety of Early Intervention in Asymptomatic Subarachnoid Neurocysticercosis Not yet recruiting NCT03950037 Phase 2 Albendazole
46 Intravenous Levetiracetam as First-line Anticonvulsive Treatment in Patients With Non-convulsive Status Epilepticus Withdrawn NCT00603135 Phase 2 first-line i/v-levetiracetam
47 Use of Lorazepam for the Treatment of Status Epilepticus Completed NCT00114569 Phase 1 lorazepam
48 High Definition Cathodal Transcranial Direct Current Stimulation for Treatment of Refractory Partial Onset Epilepsy Completed NCT02264652 Phase 1
49 A Phase I Study of Autologous Activated T-cells Targeting the CD19 Antigen and Containing the Inducible Caspase 9 Safety Switch in Subjects With Relapsed/Refractory B-cell Lymphoma Recruiting NCT03696784 Phase 1 Bendamustine;Fludarabine;AP1903;Cyclophosphamide
50 Safety and Efficacy of Intravenous Valproate in Pediatric Status Epilepticus and Acute Repetitive Seizures Unknown status NCT01268904 Valproate

Search NIH Clinical Center for Status Epilepticus

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Amobarbital
AMOBARBITAL NA PWDR
Amobarbital Sodium
Diazepam
Etomidate
fosphenytoin
Fosphenytoin sodium
Lorazepam
Midazolam
Midazolam Hydrochloride
Pentobarbital
PENTOBARBITAL NA PWDR
Pentobarbital Sodium
Propofol

Cochrane evidence based reviews: status epilepticus

Genetic Tests for Status Epilepticus

Genetic tests related to Status Epilepticus:

# Genetic test Affiliating Genes
1 Status Epilepticus 29

Anatomical Context for Status Epilepticus

MalaCards organs/tissues related to Status Epilepticus:

40
Brain, Temporal Lobe, Cortex, Amygdala, Liver, Testes, Thalamus

Publications for Status Epilepticus

Articles related to Status Epilepticus:

(show top 50) (show all 12040)
# Title Authors PMID Year
1
POLG DNA testing as an emerging standard of care before instituting valproic acid therapy for pediatric seizure disorders. 54 61
20138553 2010
2
Vascular changes in epilepsy: functional consequences and association with network plasticity in pilocarpine-induced experimental epilepsy. 54 61
20004712 2010
3
The unfolding clinical spectrum of POLG mutations. 61 54
19578034 2009
4
Elevated serum neuron-specific enolase in patients with temporal lobe epilepsy: a video-EEG study. 54 61
18595663 2008
5
Homozygous W748S mutation in the POLG1 gene in patients with juvenile-onset Alpers syndrome and status epilepticus. 61 54
18294203 2008
6
Cyclophosphamide for anti-GAD antibody-positive refractory status epilepticus. 54 61
18177354 2008
7
Nuclear factor-kappa B regulates seizure threshold and gene transcription following convulsant stimulation. 54 61
17727632 2007
8
Brain-derived neurotrophic factor (BDNF)-induced synthesis of early growth response factor 3 (Egr3) controls the levels of type A GABA receptor alpha 4 subunits in hippocampal neurons. 54 61
16901909 2006
9
Histone modifications in status epilepticus induced by kainate. 54 61
16598677 2006
10
Activation of the cannabinoid type-1 receptor mediates the anticonvulsant properties of cannabinoids in the hippocampal neuronal culture models of acquired epilepsy and status epilepticus. 61 54
16469864 2006
11
Egr3 stimulation of GABRA4 promoter activity as a mechanism for seizure-induced up-regulation of GABA(A) receptor alpha4 subunit expression. 61 54
16091474 2005
12
Reciprocal changes of CD44 and GAP-43 expression in the dentate gyrus inner molecular layer after status epilepticus in mice. 54 61
15191797 2004
13
Use of neuron-specific enolase for assessing the severity and outcome in patients with neurological disorders. 54 61
14689039 2004
14
Transient downregulation of Sema3A mRNA in a rat model for temporal lobe epilepsy. A novel molecular event potentially contributing to mossy fiber sprouting. 54 61
12821384 2003
15
Serum neuron-specific enolase in children with febrile seizures: time profile and prognostic implications. 54 61
12767459 2003
16
Normal CSF neuron-specific enolase and S-100 protein levels in patients with recent non-complicated tonic-clonic seizures. 61 54
11166790 2001
17
Knockdown of AMPA receptor GluR2 expression causes delayed neurodegeneration and increases damage by sublethal ischemia in hippocampal CA1 and CA3 neurons. 54 61
10531425 1999
18
Serum neuron-specific enolase in the major subtypes of status epilepticus. 54 61
10078721 1999
19
Status epilepticus increases CSF levels of neuron-specific enolase and alters the blood-brain barrier. 61 54
9595992 1998
20
Selective reduction of GluR2 protein in adult hippocampal CA3 neurons following status epilepticus but prior to cell loss. 54 61
9825961 1998
21
Serum NSE in status epilepticus. 61 54
8649598 1996
22
The GluR2 hypothesis: Ca(++)-permeable AMPA receptors in delayed neurodegeneration. 61 54
9246466 1996
23
Serum neuron-specific enolase in human status epilepticus. 61 54
7783877 1995
24
Is c-Jun involved in nerve cell death following status epilepticus and hypoxic-ischaemic brain injury? 54 61
8326831 1993
25
Neuroprotective and anticonvulsant effects of sinomenine in kainate rat model of temporal lobe epilepsy: Involvement of oxidative stress, inflammation and pyroptosis. 61
32430101 2020
26
Pilocarpine-induced status epilepticus reduces chemosensory control of breathing. 61
32433938 2020
27
Heparin ameliorates cerebral edema and improves outcomes following status epilepticus by protecting endothelial glycocalyx in mice. 61
32305420 2020
28
Treatment of status epilepticus with zonisamide: A multicenter cohort study of 34 patients and review of literature. 61
32417381 2020
29
Optimizing status epilepticus care during the COVID-19 pandemic. 61
32387833 2020
30
Antiepileptic drugs for acute encephalitic patients presented with seizure. 61
32442843 2020
31
Urethane attenuates early neuropathology of diisopropylfluorophosphate-induced status epilepticus in rats. 61
32283202 2020
32
Seizures associated with coronavirus infections. 61
32416567 2020
33
Continuous Electroencephalography Monitoring in Critically Ill Infants and Children. 61
32446643 2020
34
The EEG diagnosis of NCSE: Concordance between clinical practice and Salzburg Criteria for NCSE. 61
32371363 2020
35
The evolving indications of KD therapy. 61
32330835 2020
36
Characterization of organophosphate-induced brain injuries in a convulsive mouse model of diisopropylfluorophosphate exposure. 61
32359085 2020
37
Comparison of the toxicokinetics of the convulsants picrotoxinin and tetramethylenedisulfotetramine (TETS) in mice. 61
32239239 2020
38
The role of the epilepsy monitoring unit in the investigation of patients with epilepsy and intellectual disabilities. 61
32554231 2020
39
The P2X7 receptor in activated microglia promotes depression- and anxiety-like behaviors in lithium -pilocarpine induced epileptic rats. 61
32531197 2020
40
Selective hyperactivation of JNK2 in an animal model of temporal lobe epilepsy. 61
32072069 2020
41
Critically ill benign EEG variants: Is there such a thing? 61
32305854 2020
42
Ketamine in seizure management and future pharmacogenomic considerations. 61
31772310 2020
43
Central nervous system emergencies in haematological malignancies. 61
31483060 2020
44
CSF levels of a set of neurotrophic factors (brain-derived neurotrophic factor, nerve growth factor) and neuropeptides (neuropeptide Y, galanin) in epileptic children. 61
32327377 2020
45
New-Onset Refractory Status Epilepticus-Related Claustral Hyperintensities. 61
32544915 2020
46
2-Deoxyglucose terminates pilocarpine-induced status epilepticus in neonatal rats. 61
32558935 2020
47
Predictors of outcome in refractory generalized convulsive status epilepticus. 61
32524050 2020
48
Dynamic oxygen changes during status epilepticus and subsequent endogenous kindling. 61
32478859 2020
49
A Fast-Track Care by a Nursing Case Management Concept Improved Status Epilepticus Outcomes. 61
32541355 2020
50
False alarms reduction in non-convulsive status epilepticus detection via continuous EEG analysis. 61
32325447 2020

Variations for Status Epilepticus

ClinVar genetic disease variations for Status Epilepticus:

6 ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 GALC NM_000153.4(GALC):c.850G>A (p.Gly284Ser)SNV Pathogenic/Likely pathogenic 374024 rs377274761 14:88434737-88434737 14:87968393-87968393
2 GALC NM_000153.4(GALC):c.196G>A (p.Ala66Thr)SNV Likely pathogenic 374023 rs1057518843 14:88454867-88454867 14:87988523-87988523

Expression for Status Epilepticus

Search GEO for disease gene expression data for Status Epilepticus.

Pathways for Status Epilepticus

Pathways related to Status Epilepticus according to GeneCards Suite gene sharing:

(show all 17)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.56 SCN1A GRIN2B GRIA2 GRIA1 FOS
2
Show member pathways
12.46 SCN1A NTRK2 GRIN2B GRIA2 GRIA1 FOS
3 12.03 NPY JUN GRIN2B GRIA2 GRIA1 FOS
4
Show member pathways
12.01 NTRK2 JUN FOS BDNF
5 11.86 SCN1A NTRK2 NPY GRIN2B GRIA2 GRIA1
6 11.81 GFAP GAP43 FOS BDNF
7
Show member pathways
11.81 JUN GRIN2B GRIA2 GRIA1 FOS BDNF
8 11.71 GRIN2B GRIA2 GRIA1
9
Show member pathways
11.67 GRIN2B GRIA2 GRIA1
10 11.66 NTRK2 JUN GRIN2B GRIA2 GRIA1 FOS
11 11.58 GFAP GALC BDNF
12 11.29 JUN FOS CALB1
13 11.27 GRIN2B GRIA2 GRIA1 GABRA4
14 10.98 GRIN2B GRIA2 GRIA1
15 10.85 NTRK2 JUN GFAP FOS BDNF
16 10.71 NTRK2 BDNF
17 10.6 JUN FOS

GO Terms for Status Epilepticus

Cellular components related to Status Epilepticus according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 cell junction GO:0030054 9.95 NTRK2 LGI1 GRIN2B GRIA2 GRIA1 GAP43
2 neuron projection GO:0043005 9.92 GRIN2B GRIA1 GABRA4 FOS CALB1
3 postsynaptic membrane GO:0045211 9.81 GRIN2B GRIA2 GRIA1 GABRA4
4 neuronal cell body GO:0043025 9.8 SCN1A PVALB GRIA2 GRIA1 ENO2 CALB1
5 postsynaptic density GO:0014069 9.77 NTRK2 GRIN2B GRIA2 GRIA1 GAP43
6 dendritic spine GO:0043197 9.76 NTRK2 GRIA2 GRIA1 CALB1
7 axon GO:0030424 9.73 SCN1A PVALB NTRK2 GAP43 CALB1 BDNF
8 GABA-ergic synapse GO:0098982 9.72 GAP43 GABRA4 CALB1
9 terminal bouton GO:0043195 9.67 POLG NTRK2 CALB1
10 postsynaptic density membrane GO:0098839 9.65 GRIN2B GRIA2 GRIA1
11 postsynapse GO:0098794 9.55 GRIA2 GRIA1 GABRA4 CALB1 BDNF
12 cuticular plate GO:0032437 9.54 PVALB CALB1
13 dendrite GO:0030425 9.5 TRAK1 NTRK2 GRIA2 GRIA1 GAP43 CALB1
14 transcription factor AP-1 complex GO:0035976 9.43 JUN FOS
15 synapse GO:0045202 9.28 NTRK2 NPY LGI1 GRIN2B GRIA2 GRIA1

Biological processes related to Status Epilepticus according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 nervous system development GO:0007399 9.97 NTRK2 LGI1 GAP43 FOS BDNF
2 ion transmembrane transport GO:0034220 9.88 SCN1A GRIA2 GRIA1 GABRA4
3 circadian rhythm GO:0007623 9.73 NTRK2 JUN BDNF
4 learning or memory GO:0007611 9.7 GRIN2B CALB1 BDNF
5 regulation of postsynaptic membrane potential GO:0060078 9.67 GRIA2 GRIA1 GABRA4
6 regulation of synaptic plasticity GO:0048167 9.63 GRIN2B CALB1 BDNF
7 long-term synaptic potentiation GO:0060291 9.58 NTRK2 GRIN2B GFAP
8 regulation of postsynaptic cytosolic calcium ion concentration GO:0099566 9.55 GRIA1 CALB1
9 chemical synaptic transmission GO:0007268 9.55 NPY GRIN2B GRIA2 GRIA1 GABRA4
10 neuronal action potential propagation GO:0019227 9.54 SCN1A NTRK2
11 synaptic transmission, glutamatergic GO:0035249 9.54 GRIN2B GRIA2 GRIA1
12 positive regulation of non-membrane spanning protein tyrosine kinase activity GO:1903997 9.51 NTRK2 BDNF
13 feeding behavior GO:0007631 9.5 NTRK2 NPY BDNF
14 mechanoreceptor differentiation GO:0042490 9.48 NTRK2 BDNF
15 brain-derived neurotrophic factor receptor signaling pathway GO:0031547 9.43 NTRK2 BDNF
16 regulation of NMDA receptor activity GO:2000310 9.43 GRIN2B GRIA2 GRIA1
17 ionotropic glutamate receptor signaling pathway GO:0035235 9.13 GRIN2B GRIA2 GRIA1
18 modulation of chemical synaptic transmission GO:0050804 8.92 GRIN2B GRIA2 GRIA1 BDNF

Molecular functions related to Status Epilepticus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 amyloid-beta binding GO:0001540 9.58 GRIN2B GRIA2 GRIA1
2 ligand-gated ion channel activity GO:0015276 9.5 GRIN2B GRIA2 GRIA1
3 glutamate receptor activity GO:0008066 9.43 GRIN2B GRIA2 GRIA1
4 AMPA glutamate receptor activity GO:0004971 9.37 GRIA2 GRIA1
5 ion channel activity GO:0005216 9.35 SCN1A GRIN2B GRIA2 GRIA1 GABRA4
6 ionotropic glutamate receptor activity GO:0004970 9.33 GRIN2B GRIA2 GRIA1
7 transmitter-gated ion channel activity involved in regulation of postsynaptic membrane potential GO:1904315 8.92 GRIN2B GRIA2 GRIA1 GABRA4

Sources for Status Epilepticus

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....